Competence Centre on Health Technologies
Follow us on

beREADY - endometrial receptivity test

beREADY is a personalised medicine test that is designed for all women undergoing IVF treatment
beREADY guarantees that your embryo(s) are transferred at the right time.
beREADY increases the chance of getting pregnant, saving embryos, women and money.

Benefits of endometrial receptivity testing


70% of patients gave birth after first year of IVF treatment using endometrial receptivity test**


72.4% pregnancy rate was acheived by first IVF cycle when endometrial receptivity test was used**

Four fold live birth rate increase was acheived among RIF patients after endometrial receptivity test was used ***

Have you experienced IVF failure?

Find out your personal Window Of Implantation (WOI) and take advantage of the era of personalised medicine
Among recurrent implantation failure (RIF) patients, 56,7% pregnancy rate has been achieved after applying beREADY test
beREADY is extremely accurate – it detects your genes at single molecule level*
Did you know that 1 out of 3 patient experience IVF failure because the embryo is transferred too early or too late****

What does personalised medicine mean in IVF?

Genes influence your health and IVF treatment is no exception. About 30% of women have significantly displaced Window Of Implantation (WOI) and need a personalised IVF treatment plan.
Individuality in drug response affects your endometrium readiness - the inner layer of the uterus that is responsible for embryo implantation and pregnancy.
Your response to IVF treatment drugs is influenced by YOUR genes. The average IVF treatment plan does not work for everyone.

What does the beREADY test show?

The test measures the maturity level of your endometrium and enables your fertility doctor to perform the embryo transfer on the right day in the IVF cycle. The results are reported in three main categories with possible chances:


Embryo transfer should be done later in the IVF cycle


Embryo transfer can be done using the same treatment plan


Embryo transfer should be done earlier in the IVF cycle

How does the beREADY test work?

Endometrial sample

Sample shipping to beREADY lab

Sample processing and quality control

beREADY analysis and reporting

Embryo transfer at the right time

Results in 1-2 weeks

beREADY comparison with ERA test

The beREADY test has been validated under clinical conditions in IVF clinics to demonstrate the test’s accuracy. In total, 45 HRT patients’ samples were involved in a comparison against the Endometrial Receptivity Analysis (ERA, Igenomix) test. The concordance rate between two tests is 96%.

The small difference is due to the difference in testing methods. The beREADY applies a highly accurate TAC-seq DNA sequencing technology that enables beREADY to detect bio-marker molecules at a single molecule level, providing ultimate accuracy.


beREADY test uses unique patented TAC-seq sequencing technology that ensures ultimate accuracy. The original data analysis algorithm is published* and adjusted to diagnostic assay.

Referred publications and research behind beREADY test

Teder et al., TAC-seq: targeted DNA and RNA sequencing for precise biomarker molecule counting. 2018, npj Genomic Medicine, PubMed ID 30588329 Link to original study

** Simón et al. A 5-year Multicenter Randomized Controlled Trial of In Vitro Fertilization with Personalized Blastocyst Transfer versus  Frozen or Fresh Transfer. 2020, Reproductive BioMedicine Online, PubMed ID 32723696. Link to original study

*** Haouzi et al. Customized Frozen Embryo Transfer after Identification of the Receptivity Window with a Transcriptomic Approach Improves the Implantation and Live Birth Rates in Patients with Repeated Implantation Failure. 2021, Reproductive Sciences, PubMed ID 32725589. Link to original study

**** Ruiz-Alonso et al., The endometrial receptivity array for diagnosis and personalized embryo transfer as a treatment for patients with repeated implantation failure. 2013, Fertility and Sterility, PubMed ID 23756099. Link to original study

Saare et al., A molecular tool for menstrual cycle phase dating in endometriosis transcriptomic studies. 2019, Biology of Reproduction, PubMed ID 31004479 Link to original study

Suhorutshenko et al., Endometrial receptivity revisited: endometrial transcriptome adjusted for tissue cellular heterogeneity. 2018, Human Reproduction, PubMed ID 30295736 Link to original study

Altmäe et al., Meta-signature of human endometrial receptivity: a meta-analysis and validation study of transcriptomic biomarkers. 2018, Scientific Reports, PubMed ID 28855728 Link to original study

Krjutškov et al., Single-cell transcriptome analysis of endometrial tissue. 2016, Human Reproduction, PubMed ID 26874359 Link to original study